Terbinafine hydrochloride
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Tinea Capitis
Conditions
Tinea Capitis
Trial Timeline
Jul 1, 2004 → Apr 1, 2006
NCT ID
NCT00117754About Terbinafine hydrochloride
Terbinafine hydrochloride is a phase 3 stage product being developed by Novartis for Tinea Capitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00117754. Target conditions include Tinea Capitis.
What happened to similar drugs?
3 of 10 similar drugs in Tinea Capitis were approved
Approved (3) Terminated (1) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002394 | Pre-clinical | Completed |
| NCT00117754 | Phase 3 | Completed |
Competing Products
20 competing products in Tinea Capitis